@Shapeshifter Yes, there are plenty of negatives/risks for ANG that were discussed in the pod, as you have mentioned. We have also discussed most of these here on Strawman.
My intention here was to point out some of the metrics that weren’t discussed in the pod which I thought Chris might have raised in his investment case. Claude did a great job of raising most of the weaknesses.
Chile is no doubt a debacle and a black mark against management. It will be critical for management to turn the Chile business around quickly to regain any credibility in the market.
In regards to ANG’s underlying figures, I have been ignoring these when it comes to assessing business performance. The metrics I’ve quoted above are all based on statutory results, not underlying. I don’t think it’s a been a great look for management to adjust FY24 and FY25 reported statutory figures especially when it’s in favour of FY25. Nor is it a good look to present underlying figures 54% higher than the statutory figures, and then to quote their ROE in their reports on the underlying figures (28% rather than 19% based on statutory NPAT).
While the business is capital intensive, the return on capital over the last 5 years has been high for a capital intensive business ( FY21 12%, FY22 18%, FY23 10%, FY24 23%, and FY25 17%, based on statutory results).
I need to do more work on ANG’s competitor's @Shapeshifter. My assumption has been that the high ROE (19% - 20%) indicates they have a competitive edge. This could be a dangerous assumption so I will investigate ANG’s competitors more thoroughly and put this together in a separate straw. It’s something I need to get my head around with more confidence.
Thanks for raising these issues. It’s always good to get a more balanced perspective! Helps you to become a better investor! :)